Skip to main content
. 2021 Dec 24;60(Suppl 6):vi21–vi28. doi: 10.1093/rheumatology/keab498

Fig. 1.


Fig. 1

Targeted therapies used for the treatment or currently used in clinical trials in SLE

APC: antigen presenting cell; BAFF: B-cell activating factor; BDCA2: blood dendritic cell antigen 2; BTK: Bruton’s tyrosine kinase; CD40L: CD40 ligand; IFNR: IFN receptor; JAK: Janus kinase